Aécio A Braga1, Raul H Bortolin1, Magda E Graciano-Saldarriaga1, Thiago Dc Hirata1, Alvaro Cerda2, Renata Cc de Freitas1, Hui T Lin-Wang3, Jessica B Borges3, João Id França4, Laureane N Masi5, Rui Curi5, Tania C Pithon-Curi5, Marcelo F Sampaio6,7, Lara R Castro6,7, Gisele M Bastos3,8, Rosario Dc Hirata1, Mario H Hirata1. 1. Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil. 2. Department of Basic Sciences, Center of Excellence in Translational Medicine, CEMT-BIOREN, Universidad de La Frontera, Temuco 4810296, Chile. 3. Molecular Research Laboratory in Cardiology, Institute Dante Pazzanese of Cardiology, Sao Paulo 04012-909, Brazil. 4. Laboratory of Epidemiology and Statistics, Institute Dante Pazzanese of Cardiology, Sao Paulo 04012-909, Brazil. 5. Interdisciplinary Post-graduate Program in Health Sciences, Cruzeirodo Sul University, Sao Paulo 01506-000, Brazil. 6. Medical Clinic Division, Institute Dante Pazzanese of Cardiology, Sao Paulo 04012-909, Brazil. 7. Department of Cardiology, Real e Benemerita Associação Portuguesa de Beneficiência, Sao Paulo 01323-001, Brazil. 8. Department of Teaching and Research, Real e Benemerita Associação Portuguesa de Beneficiencia, Sao Paulo 01323-001, Brazil.
Abstract
Aim: To explore the association of circulating miRNAs with adiposity, metabolic status and inflammatory biomarkers in patients with metabolic syndrome (MetS). Methods: Serum levels of 372 miRNAs were measured in patients with (n = 6) and without MetS (n = 6) by quantitative PCR array, and dysregulated miRNAs were validated in a larger cohort (MetS, n = 89; non-MetS, n = 144). Results: In the screening study, seven miRNAs were dysregulated in patients with MetS, and miR-421 remained increased in the validation study. miR-421 was associated with a high risk of MetS and insulin resistance and hypertension and correlated with glycated hemoglobin, triacylglycerols, high-sensitivity CRP, IL-6, resistin and adiponectin (p < 0.05). Conclusion: Circulating miR-421 is a potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.
Aim: To explore the association of circulating miRNAs with adiposity, metabolic status and inflammatory biomarkers in patients with metabolic syndrome (MetS). Methods: Serum levels of 372 miRNAs were measured in patients with (n = 6) and without MetS (n = 6) by quantitative PCR array, and dysregulated miRNAs were validated in a larger cohort (MetS, n = 89; non-MetS, n = 144). Results: In the screening study, seven miRNAs were dysregulated in patients with MetS, and miR-421 remained increased in the validation study. miR-421 was associated with a high risk of MetS and insulin resistance and hypertension and correlated with glycated hemoglobin, triacylglycerols, high-sensitivity CRP, IL-6, resistin and adiponectin (p < 0.05). Conclusion: Circulating miR-421 is a potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.
Authors: Carmen Peña-Bautista; Lourdes Álvarez-Sánchez; Antonio José Cañada-Martínez; Miguel Baquero; Consuelo Cháfer-Pericás Journal: Biomedicines Date: 2021-12-02